PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-05 · 125 (1) · 203-213
DOI: 10.1016/j.ijrobp.2025.03.033 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-05. Verfasst von Maneesh Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Ins…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Positron Emission Tomography Computed Tomography, Adenocarcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Varian Medical Systems Inc.
Abstract (Originalsprache)
PURPOSE: To assess the safety of using combined Gallium68-prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) (68Ga-PSMA-PET/CT) and multiparametric magnetic resonance imaging (mpMRI) for planning dominant intraprostatic lesion (DIL) boost in prostate stereotactic radiation therapy (SBRT) for dose escalation (PROBE). METHODS AND MATERIALS: Patients with intermediate- or high-risk prostate adenocarcinoma with DIL identified on mpMRI and 68Ga-PSMA-PET/CT and suitable for SBRT were enrolled in this phase 2 trial. 68Ga-PSMA-PET/CT was fused with mpMRI for gross tumor volume (GTV) delineation. Semiautomatic contouring of DIL was performed using 20% to 90% of the maximum standardized uptake value (SUVmax) (DILx%). Concordance metrics were used to select the DILx% matching closest to GTVMRI (GTVPET). Prostate (36.25 Gy), pelvic nodes (25 Gy), GTVunion: GTVPET ∪ GTVMRI (40 Gy), and GTVoverlap: GTVPET ∩ GTVMRI (42.5 Gy) were planned for 5-fraction SBRT. All patients received androgen deprivation therapy (ADT) for 6 months. The primary endpoint for the present analysis was concordance (volumetric and spatial) between GTVMRI and GTVPET. Secondary endpoints included the percentage SUVmax threshold for GTVPET contouring (%SUVGTV-PET) and cumulative acute (≤90 days) urinary and gastrointestinal toxicity using Common Terminology Criteria for Adverse Event (CTCAE) v5.0. RESULTS: Thirty patients (54% intermediate risk, 46% high risk) were enrolled. GTVMRI and GTVPET showed strong volumetric correlation (Spearman correlation coefficient ρ = 0.817, 95% CI, 0.64-0.91; P < .001). The median Dice similarity coefficient, Jaccard index, and the mean Hausdorff distance for PET and magnetic resonance imaging boost volumes were 0.56, 0.37, and 2.2, respectively. The median %SUVGTV-PET was 48% (IQR, 40%-58%). There was an inverse correlation between DIL SUVmax and %SUVGTV-PET (Spearman correlation coefficient ρ = -0.598, 95% CI lower -0.79, upper -0.29; P < 0.001). Cumulative grade 2 acute urinary and GI toxicity were 13.3% and 6.6%, respectively, with no grade ≥3 toxicities. CONCLUSION: Boost volumes on 68Ga-PSMA-PET/CT and mpMRI were volumetrically similar, however, with poor spatial concordance. The %SUVmax threshold for GTVPET contouring correlated inversely with DIL SUVmax and was a median of 48%. Based on the favorable acute toxicity profile, PSMA-PET-guided intraprostatic boost is likely to be safe for dose escalation in prostate SBRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Department of Radiodiagnosis, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Department of Nuclear Medicine, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Department of Medical Physics, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Clinical Research Secretariat, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India.
- Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer, Homi Bhabha National Institute, Mumbai, India. Electronic address: vedangmurthy@gmail.com.
Förderung
- Varian Medical Systems Inc
Zitieren
APA
Singh, M., Katdare, A., Ghosh, S., Choudhury, S., Phurailatpam, R., Patil, D., Tiwari, M., Anaz, M., Chougle, N. H., Sable, N., Agrawal, A., Pawar, A., Rangarajan, V., Maitre, P., & Murthy, V. (2026). PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics, 125(1), 203-213. https://doi.org/10.1016/j.ijrobp.2025.03.033
Vancouver
Singh M, Katdare A, Ghosh S, Choudhury S, Phurailatpam R, Patil D, et al. PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;125(1):203-213. doi:10.1016/j.ijrobp.2025.03.033
BibTeX
@article{Singh2026,
author = {Singh, Maneesh and Katdare, Aparna and Ghosh, Suchismita and Choudhury, Sayak and Phurailatpam, Reena and Patil, Divya and Tiwari, Mahima and Anaz, Muhammed and Chougle, Nazneen Husain and Sable, Nilesh and Agrawal, Archi and Pawar, Akash and Rangarajan, Venkatesh and Maitre, Priyamvada and Murthy, Vedang},
title = {PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {125},
number = {1},
pages = {203--213},
doi = {10.1016/j.ijrobp.2025.03.033}
}
EUVIMED